Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30results about How to "Adverse side-effect" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Markers for cancer prognosis and therapy and methods of use
InactiveUS20130042333A1Adverse side effectLow costBiocideMicrobiological testing/measurementAdjuvantTreatment field
The invention relates generally to the field of cancer prognosis and treatment. More particularly, the present invention relates to methods and compositions that utilize a particular panel of gene products (“biomarkers”) and their differential expression patterns (“expression signatures”), wherein the expression patterns correlate with responsiveness, or lack thereof, to chemotherapy treatment. The invention is based on the identification of a specific set of biomarkers that are differentially expressed in chemotherapy-treated tumors and which are useful in predicting the likelihood of a therapeutic response, including residual disease persistence and subsequent tumor recurrence in cancer patients receiving chemotherapy. The gene panel is also useful in designing specific adjuvant modalities with improved therapeutic efficiency. Also disclosed are methods for characterizing tumors according to expression of the biomarkers described herein.
Owner:GEN TECH
Methods and pharmaceutical compositions for healing wounds
InactiveUS20060258562A1Effectively circumventedEnhance healing processPeptide/protein ingredientsGenetic material ingredientsSkin cellPkc isoforms
Methods and pharmaceutical compositions for inducing or accelerating a healing process of a damaged skin or skin wound, comprise modulating expression and / or activity of at least two PKC isoforms in skin cells colonizing the damaged skin or skin wound area.
Owner:BAR ILAN UNIV
Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
InactiveUS20100286186A1Low variabilityReduction and elimination of painBiocideNervous disorderSide effectAmino acid side chain
The present invention concerns dicarboxylic acid linked amino acid and peptide prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, decreasing the adverse GI side effects of the opioid analgesic and increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are also provided. In one embodiment, prodrugs having the amino acid side chains of valine, leucine, isoleucine and glycine; and mono-, di- and tripeptides thereof are provided.
Owner:SHIRE PLC
Low defect pre-emitter and pre-base oxide etch for bipolar transistors and related tooling
InactiveUS6858532B2Adverse side-effectSuppressed undercutSemiconductor/solid-state device manufacturingSemiconductor devicesCapacitanceEngineering
An oxide etch process is described which may be used for emitter and base preparation in bipolar SiGe devices. The low temperature process employed produces electrical insulation between the emitter and base by a COR etch which preserves insulating TEOS glass. The insulating TEOS glass provides reduced capacitance and helps to achieve high speed. An apparatus is also described for practicing the disclosed process.
Owner:GLOBALFOUNDRIES INC
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
InactiveUS20060003950A1Reduce incidenceReduce riskBiocideCarbohydrate active ingredientsAnticarcinogenActive Vitamin D
The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.
Owner:BONE CARE INT
Treatment method against side-effects of chemotherapy
InactiveUS6979688B2Preserving anti-cancer systemic efficacyAdverse side effectBiocideKetone active ingredientsSide effectWhole body
A method and composition is provided for organ rescue wherein a specific counter-measure is applied locally to a tissue at risk for or exhibiting an adverse side effect of a cancer treatment. More particularly, the method and composition is directed at controlling Hand-Foot Syndrome, a painful redness and cracking of the skin of the hands and feet which can occur with systemic treatment with 5-fluorouracil or a precursor thereof. Uracil ointment is applied to the skin of the hands and feet to prevent Hand-Foot Syndrome which can occur from systemic administration of 5-fluorouracil (or precursor thereof) as cancer treatment.
Owner:ASYMMETRIC THERAPEUTICS
Compositions and Methods for Treating or Preventing Inflammatory Bowel Disease, Familial Adenomatous Polyposis and Colon Cancer
ActiveUS20080031984A1Prevent and reduce incidenceAdverse side-effectBiocideOrganic active ingredientsIntestinal structureUlcerative colitis
The present invention provides methods for preventing colon cancer by administering, to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to prevent colon cancer, which composition inhibits COX-2. The present invention also provides methods for treating inflammation locally in the intestines comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat inflammation. In one embodiment, the polymeric proanthocyanidin compound is crofelemer. The present invention in alternative embodiments provides methods for treating pain locally in the intestines and treating inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, as well as for treating familial adenomatous polyposis (FAP).
Owner:NAPO PHARMA INC
Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders
InactiveUS20050261210A1Suppresses genetic basisAdverse side-effectBiocideCarbohydrate active ingredientsDiseaseSuppressor
The invention features methods of treating a inherited or acquired cutaneous or gastrointestinal (GI) disorder caused by or having a symptom caused by a nonsense mutation by local administration of a nonsense suppressor agent (e.g., an aminoglycoside or nucleic acid encoding a suppressor tRNA) to the skin or intraluminal GI surface so as to provide for phenotypic suppression of the nonsense mutation.
Owner:RGT UNIV OF CALIFORNIA
Tannin formulation for treating GI spasms
ActiveUS8716352B1Reduced activityWorsen existing gastrointestinal conditionBiocideIn-vivo radioactive preparationsDiseaseSide effect
Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.
Owner:LIVELEAF HLDG LLC
Method of administering conjugates
InactiveUS20100272675A1EliminateDrug resistancePeptide/protein ingredientsSkeletal disorderAdjuvantHapten
The invention relates to a method of treating a host animal to eliminate pathogenic cells. The method comprises the steps of administering to the host animal a hapten-carrier conjugate, administering to the host animal a TH-I biasing adjuvant, and administering to said host animal a ligand conjugated to a hapten herein the ligand-hapten conjugate is administered during the first cycle of therapy with the hapten-carrier conjugate. The invention also relates to the same method wherein the ratio of the hapten-carrier conjugate to the TH-I biasing adjuvant on a weight to weight basis ranges from about 1:10 to about 1:1.
Owner:ENDOCTYE INC
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors
InactiveUS7348140B1Less susceptibilityLess to decreased riskMicrobiological testing/measurementBiological testingMedicineG protein-coupled receptor
The invention provides compositions and methods for screening individuals for the presence of G-protein coupled receptor (GPCR) variants. The compositions and methods are useful for determining clinical outcome of drug therapy or for tailoring drug therapy for the individual based upon the presence or absence of one or more GPCR variants in the subject.
Owner:ACADIA PHARMA INC
Anti-fatty liver agent
ActiveUS20100129333A1Low toxicityUse of materialBiocideMilk preparationFatty liverLactic acid bacterium
Disclosed is an anti-fatty liver agent comprising a cell and / or a culture obtained by culturing a lactic acid bacterium belonging to Latobacillus gasserti as an active ingredient. Also disclosed is a pharmaceutical agent having an anti-fatty liver activity or an anti-fatty liver beverage / food comprising a cell and / or a culture obtained by culturing a lactic acid bacterium belonging to Latobacillus gasserti as an active ingredient.
Owner:SNOW BRAND MILK PROD CO LTD
Anti-cancer drug
ActiveUS20110081356A1Improved cancer therapeutic effectEnhancement in cancer therapeutic effectHeavy metal active ingredientsOrganic active ingredientsMedicineBULK ACTIVE INGREDIENT
Owner:THE UNIV OF TOKYO
Cancer treatment
InactiveUS6284799B1Improve inflammatory responseGood tumor growthBiocideAnimal repellantsMedicineCancer therapy
The present invention is concerned with the identification of compounds which increase the therapeutic index of chemotherapy drugs and which stimulate the growth of cancers, their use in the treatment of cancer and with certain novel compounds useful in such treatment.
Owner:UNIVERSITY OF MANITOBA
Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
ActiveUS20160000864A1Facilitate killingEfficient killingOrganic active ingredientsPeptide/protein ingredientsActive agentLung cancer
The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence.
Owner:CHEER GLOBAL
Anti-cancer drug
ActiveUS9226934B2Improve anti-cancer effectGood treatment effectHeavy metal active ingredientsOrganic active ingredientsMedicineCancer therapy
Owner:THE UNIV OF TOKYO
Organic compounds
ActiveUS20140205596A1Increase awarenessLess lipophilicBiocideHeavy metal active ingredientsDiseaseMedicine
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
Owner:INTRA CELLULAR THERAPIES INC
Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
ActiveUS9814759B2Efficient killingEffective treatmentOrganic active ingredientsPeptide/protein ingredientsLymphatic SpreadActive agent
The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence.
Owner:CHEER GLOBAL
Treatment method against side-effects of chemotherapy
InactiveUS20050215514A1Preserving anti-cancer systemic efficacyAdverse side effectBiocideCarbohydrate active ingredientsUracil OintmentSide effect
A method and composition is provided for organ rescue wherein a specific counter-measure is applied locally to a tissue at risk for or exhibiting an adverse side effect of a cancer treatment. More particularly, the method and composition is directed at controlling Hand-Foot Syndrome, a painful redness and cracking of the skin of the hands and feet which can occur with systemic treatment with 5-fluorouracil or a precursor thereof. Uracil ointment is applied to the skin of the hands and feet to prevent Hand-Foot Syndrome which can occur from systemic administration of 5-fluorouracil (or precursor thereof) as cancer treatment.
Owner:ASYMMETRIC THERAPEUTICS
Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
ActiveUS8852649B2Prevent and reduce incidenceAdverse side-effectOrganic active ingredientsBiocideIntestinal structureMedicine
Methods for treating colon cancer include administering, to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat colon cancer, which composition inhibits COX-2. Methods for treating inflammation locally in the intestines comprise administering, to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat inflammation. In one embodiment, the polymeric proanthocyanidin compound is crofelemer.
Owner:NAPO PHARMA INC
Organic compounds
ActiveUS20180333403A1Lower blood sugar levelsLess lipophilicOrganic active ingredientsMetabolism disorderDiseaseNK1 receptor antagonist
The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.
Owner:INTRA CELLULAR THERAPIES INC
Anti-fatty liver agent
Disclosed is an anti-fatty liver agent comprising a cell and / or a culture obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri as an active ingredient. Also disclosed is a pharmaceutical agent having an anti-fatty liver activity or an anti-fatty liver beverage / food comprising a cell and / or a culture obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri as an active ingredient.
Owner:SNOW BRAND MILK PROD CO LTD
Factor H potentiating antibodies and uses thereof
ActiveUS11377487B2Strong inhibitory activityGreat potentialImmunoglobulins against animals/humansAntibody ingredientsDiseaseAntiendomysial antibodies
Owner:STICHTING SANQUIN BLOEDVOORZIENING
Factor h potentiating antibodies and uses thereof
ActiveUS20210054059A1High binding affinityStrong inhibitory activityImmunoglobulins against animals/humansAntibody ingredientsDiseaseAntiendomysial antibodies
The invention relates to novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation.
Owner:STICHTING SANQUIN BLOEDVOORZIENING
Composition for modulating the expression of cell adhesion molecules
InactiveUS20140017247A1Reducing cell adhesion molecule expressionPreventing and treating cytokine mediated inflammatoryAntibacterial agentsAntipyreticAdhesion processNeural cell adhesion molecule
A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.
Owner:GLENVEIGH PHARMA
Organic compounds
ActiveUS11491150B2Less lipophilicMore polarOrganic active ingredientsMetabolism disorderDiseaseNephrosis
The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.
Owner:INTRA CELLULAR THERAPIES INC
Combination therapies with cannabis plant extract
InactiveUS20190321426A1Adverse side-effectEliminate side effectsNervous disorderHydroxy compound active ingredientsCannabisMedicine
Owner:TIKUN OLAM
Topical cosmetic composition
ActiveUS10463601B1Lack of skin tautness and supplenessInduction of photosensitivityCosmetic preparationsToilet preparationsWrinkle skinVitamin C
A method of preparation of a topical composition for wrinkle or lines reduction when applied to face and neck is disclosed. The method of preparation of topical composition uses the following ingredients: Purified Water, Vitamin C tablets (natural 1000 mg), Vitamin E capsules (natural 1000 mg), emulsified wax, Essential Oils (Argan, Johoba, Coconut, & Lavender, Tea Tree Oil), & Cornstarch. The method of preparation of topical composition uses the following amounts of each ingredient: 2¾ cup Purified Water 12 Vitamin C Tablets; 15 Vitamin E Capsules; 1 Tablespoon plus ¾ teaspoon Emulsified Wax granules; 1 Tablespoon Johoba Oil; 2 teaspoons Argan Oil; 2 teaspoons Coconut Oil; 4 Tablespoons Cornstarch; ½ teaspoon Lavender Oil, 0.03 ounces Tea Tree Oil or 1 cubic centimeter (cc) syringe. The topical composition can be used with minor changes for both genders with equal effectiveness.
Owner:DILLON LORITA
Anti-fatty liver agent
ActiveUS20140140972A1Low toxicityUse of materialBiocideBacteria material medical ingredientsLactic acid bacteriumFatty liver
An anti-fatty liver agent containing a cell and / or a culture of the lactic acid bacterium Latobacillus gasseri as an active ingredient is provided. Also disclosed is a pharmaceutical agent having an anti-fatty liver activity or an anti-fatty liver beverage or food containing a cell and / or a culture of the lactic acid bacterium Latobacillus gasseri as an active ingredient. Methods of treating fatty liver in a subject by administering a cell and / or a culture of the lactic acid bacterium Latobacillus gasseri are also provided.
Owner:SNOW BRAND MILK PROD CO LTD
Anti-fatty liver agent
An anti-fatty liver agent containing a cell and / or a culture of the lactic acid bacterium Latobacillus gasseri as an active ingredient is provided. Also disclosed is a pharmaceutical agent having an anti-fatty liver activity or an anti-fatty liver beverage or food containing a cell and / or a culture of the lactic acid bacterium Latobacillus gasseri as an active ingredient. Methods of treating fatty liver in a subject by administering a cell and / or a culture of the lactic acid bacterium Latobacillus gasseri are also provided.
Owner:SNOW BRAND MILK PROD CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com